UNSPSC 51422122: Mometasone furoate monohydrate

This classification denotes a therapeutic glucocorticoid C27H30Cl2O6.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MTW0WEG809, chemically known as pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- monohydrate, but more generally known as mometasone furoate monohydrate, which bears US NIH Compound Identifier 55188.

UNSPSC 51422122 Mometasone furoate monohydrate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local solicitation activity under this code shows little alignment with that scope. The single recent opportunity on file — Seminole County, Florida's IFB 60459723LAS posted June 30, 2026 — solicits naloxone and drug deactivation systems for community health support, which falls outside the code's pharmaceutical formulation taxonomy. State and local procurement offices appear to use this code inconsistently or as a catchall for emergency-response pharmaceuticals and medical supplies rather than as a precision classification for mometasone furoate products.

Seminole County is the sole issuing body with recent activity under this code. The opportunity calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive bid process, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The contract includes a two-year initial term with a one-year renewal option, E-Verify compliance requirements, and standard insurance and drug-free workplace certifications. No geographic spread beyond Florida emerges from available recent records, and no additional representative opportunities appear in the dataset. The mismatch between the code's nominal scope and the naloxone procurement suggests this code warrants close scrutiny before pursuit — either reclassification is occurring, or the code is not actively used for its intended pharmaceutical product line in state and local markets.